Medical device company Ablatus Therapeutics Ltd, has been founded to develop and commercialise a novel tissue ablation technology to treat the most challenging and often inoperable, solid cancer tumours. Spun-out of Norfolk & Norwich University Hospitals NHS Foundation Trust (NNUH) with support from Health Enterprise East (HEE), investment totalling £500K comes from Anglia Capital Group, […]
UK government-created and EU-backed institutions support Ablatus Therapeutics in its $648,000 round to commercialise a potential treatment for solid cancer tumours. Ablatus Therapeutics, a UK-based medical device spinout from Norfold and Norwich University Hospitals NHS Foundation Trust, has raised £500,000 ($648,000) from a consortium including the Low Carbon Innovation Fund. The Low Carbon Innovation Fund, […]
Ablatus Therapeutics Ltd, a medical device company, has been founded to develop and commercialise a novel tissue ablation technology to treat the most challenging and often inoperable, solid cancer tumours. Spin out company raises £500k seed funding to progress development towards CE-marking and human studies The start-up company has spun-out of Norfolk & Norwich University […]
A Future50 firm targeting a breakthrough in cancer treatment has moved a step closer to developing life-saving treatment after completing a half-million pound funding round. Ablatus Therapeutics is the first commercial spin-out from the Norfolk and Norwich University Hospital, which has a stake in the company, and builds on research which identified a more efficient […]
